# Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

> **NCT01985334** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4389 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Glycopyrronium
- **DRUG:** SABA
- **DRUG:** LABA
- **DRUG:** Indacaterol maleate and glycopyrronium bromide
- **DRUG:** LAMA
- **DRUG:** SAMA
- **DRUG:** ICS

## Key facts

- **NCT ID:** NCT01985334
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-14
- **Primary completion:** 2016-04-29
- **Final completion:** 2016-04-29
- **Target enrollment:** 4389 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01985334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01985334, "Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01985334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*